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ABSTRACT Paenibacillus larvae, the causative agent of American foulbrood (AFB), is
the primary bacterial pathogen affecting honeybees and beekeeping. The main
methods for controlling AFB are incineration of diseased colonies or prophylactic an-
tibiotic treatment (e.g., with tylosin), neither of which is fully satisfactory. The search
for superior means for controlling AFB has led to an increased interest in the natural
relationships between the honeybee-pathogenic and mutualistic microorganisms
and, in particular, the antagonistic effects of honeybee-speciﬁc lactic acid bacteria
(hbs-LAB) against P. larvae. These effects have been demonstrated only on individual
larvae in controlled laboratory bioassays. Here we investigated whether supplemen-
tal administration of hbs-LAB had a similar beneﬁcial effect on P. larvae infection at
colony level. We compared experimentally AFB-infected colonies treated with hbs-
LAB supplements to untreated and tylosin-treated colonies and recorded AFB symp-
toms, bacterial spore levels, and two measures of colony health. To account for the
complexity of a bee colony, we focused on (Bayesian) probabilities and magnitudes
of effect sizes. Tylosin reduced AFB disease symptoms but also had a negative effect
on colony strength. The tylosin treatment did not, however, affect P. larvae spore
levels and might therefore “mask” the potential for disease. hbs-LAB tended to re-
duce brood size in the short term but was unlikely to affect AFB symptoms or
spores. These results do not contradict demonstrated antagonistic effects of hbs-LAB
against P. larvae at the individual bee level but rather suggest that supplementary
administration of hbs-LAB may not be the most effective way to harness these ben-
eﬁcial effects at the colony level.
IMPORTANCE The previously demonstrated antagonistic effects of honeybee-derived
bacterial microbiota on the infectivity and pathogenicity of P. larvae in laboratory
bioassays have identiﬁed a possible new approach to AFB control. However, honey-
bee colonies are complex superorganisms where social immune defenses play a ma-
jor role in resistance against disease at the colony level. Few studies have investi-
gated the effect of beneﬁcial microorganisms on bee diseases at the colony level.
Effects observed at the individual bee level do not necessarily translate into similar
effects at the colony level. This study partially ﬁlls this gap by showing that, unlike
at the individual level, hbs-LAB supplements did not affect AFB symptoms at the
colony level. The inference is that the mechanisms regulating the honeybee micro-
bial dynamics within a colony are too strong to manipulate positively through sup-
plemental feeding of live hbs-LAB and that new potential remedies identiﬁed
through laboratory research have to be tested thoroughly in situ, in colonies.
KEYWORDS American foulbrood, Apis mellifera, Biﬁdobacterium, Lactobacillus,
Paenibacillus larvae, enzootic disease, honeybee-speciﬁc lactic acid bacteria,
honeybees, host-pathogen dynamics, tylosin
Citation Stephan JG, Lamei S, Pettis JS,
Riesbeck K, de Miranda JR, Forsgren E. 2019.
Honeybee-speciﬁc lactic acid bacterium
supplements have no effect on American
foulbrood-infected honeybee colonies. Appl
Environ Microbiol 85:e00606-19. https://doi
.org/10.1128/AEM.00606-19.
Editor Andrew J. McBain, University of
Manchester
Copyright © 2019 Stephan et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.
Address correspondence to Jörg G. Stephan,
jorg.stephan@slu.se.
* Present address: Sepideh Lamei, Recipharm
AB, Karlskoga, Sweden; Jeffery S. Pettis, Pettis
and Associates LLC, Salisbury, Maryland, USA.
J.G.S. and S.L. contributed equally to the
manuscript.
Received 15 March 2019
Accepted 11 April 2019
Accepted manuscript posted online 19
April 2019
Published
ENVIRONMENTAL MICROBIOLOGY
crossm
July 2019 Volume 85 Issue 13 e00606-19 aem.asm.org 1Applied and Environmental Microbiology
17 June 2019
 o
n
 O
ctober 30, 2019 at SVERIG
ES LANTBRUKSUNIVERSITET
http://aem
.asm
.org/
D
ow
nloaded from
 
 o
n
 O
ctober 30, 2019 at SVERIG
ES LANTBRUKSUNIVERSITET
http://aem
.asm
.org/
D
ow
nloaded from
 
 o
n
 O
ctober 30, 2019 at SVERIG
ES LANTBRUKSUNIVERSITET
http://aem
.asm
.org/
D
ow
nloaded from
 
 o
n
 O
ctober 30, 2019 at SVERIG
ES LANTBRUKSUNIVERSITET
http://aem
.asm
.org/
D
ow
nloaded from
 
European honeybees, Apis mellifera, are social insects with a diverse microbiota.Recent surveys have shown the presence of dozens of bacterial taxa in adult
honeybees, ranging from Gram-positive bacteria to alpha-, beta-, and gammaproteo-
bacteria. While the majority of these bacterial species are not associated with any
honeybee disease (1–3), a minority are clearly pathogenic. One of the major patholog-
ical threats to honeybees is the spore-forming bacterium Paenibacillus larvae, the
causative agent of American foulbrood (AFB), the most lethal brood disease of bees
(4–7). Young larvae ingest P. larvae spores with the food provided by the nurse bees.
The spores germinate and proliferate in the midgut and invade the larval tissue, where
they continue to multiply and produce billions of spores. The spores are extremely
resilient and can remain viable for decades (64). The larval remains (scales) are difﬁcult
to remove by honeybees and provide a continuous source of infection for new cycles
of brood, which, together with the hardiness and viability of the spores, are the key
factors driving the lethality and epidemiology of AFB (4, 8). The spores are distributed
within colonies by young honeybees performing in-hive tasks, such as cleaning and
nursing larvae, and between colonies by swarming, robbing, and in particular by
beekeepers moving contaminated material between colonies (9, 10).
There are two main approaches for the control of AFB. The ﬁrst is to target the
long-lived spores by burning the contaminated frames, the hive bodies, and the bees,
although the latter can sometimes be saved as an artiﬁcial swarm housed on new
material (11, 65). The second therapeutic approach is to target the germinating bacteria
with antibiotics (e.g., oxytetracycline or the macrolide tylosin), whose prophylactic use
in certain countries has inevitably led to antibiotic resistance in P. larvae (12, 13). Such
antibiotics mitigate AFB symptoms, thus avoiding regulatory requirements for inciner-
ation, but do not kill the bacterial spores, which remain viable in the hive environment.
The artiﬁcial suppression of clinical symptoms, coupled with a lack of preventative
management practices, masks the accumulated potential for disease outbreak (14, 15)
without eliminating the causative disease agent (16, 17). The infection pressure from
the persistent, infective spores will aid the infection of other colonies and facilitate
selection for resistant P. larvae strains.
The recent discovery of the strong antagonistic effect of bacterial microbiota on the
infectivity and pathogenicity of P. larvae has identiﬁed a new potential approach to AFB
control, through the honeybee microbial defenses (18–21). Among the beneﬁcial
bacteria associated with honeybees, species belonging to the lactobacilli and biﬁdo-
bacteria are thought to have health-promoting effects on honeybees, through activat-
ing the honeybees’ immune defenses (21, 22), producing antimicrobial compounds
inhibiting bacterial competitors (23–25), and efﬁciently outcompeting pathogenic bac-
teria for common resources (3, 18, 19). Previously, 13 species of honeybee-speciﬁc lactic
acid bacteria (hbs-LAB) were isolated from the honey crop of honeybees (26, 27). Both
biﬁdobacteria and lactobacilli are included in the LAB deﬁnition due to their similar
origin, their organic acid production, and their functional similarity in use by the food
and biotech industries (28). hbs-LAB produce a range of metabolites, such as organic
acids (27) and extracellular proteins that are secreted upon exposure to various
microbial stressors, including lipopolysaccharide and lipoteichoic acid (29). It has been
shown repeatedly that hbs-LAB, both individually (23, 25) and in combination (30), have
inhibitory effects on P. larvae under laboratory conditions in both microbial inhibition
assays and infection bioassays.
However, the honeybee colony is a complex superorganism with both individual
and social immune defenses that work in tandem to manage overall colony health but
lead to different consequences for infected individuals. Beneﬁcial health effects ob-
served at the individual bee level therefore do not necessarily translate into similar
effects at the colony level (31–34). There have been several attempts to assess the effect
of beneﬁcial microbes on honeybee health at the colony level (18, 19, 35). Some studies
show that beneﬁcial microbes (Lactobacillus rhamnosus) increase honeybee mortality
(35), whereas other investigations suggest that beneﬁcial microbes (Lactobacillus aci-
dophilus and Biﬁdobacterium lactis) affect honeybee colonies positively, increasing
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honey production (18, 19). In a previous study we demonstrated through laboratory
bioassays the inhibitory effects of oral administration of hbs-LAB on P. larvae infection
in honeybee larvae at the individual level (36). We have subsequently shown that
hbs-LAB inhibit the growth of P. larvae in larvae through extracellular secreted antimi-
crobial substances (30).
The aim of this study was to determine whether the inhibitory effects of hbs-LAB
observed in individual larval bioassays could be replicated in honeybee colonies
through oral administration of hbs-LAB supplements and how effective it was relative
to antibiotic treatment in inhibiting disease development. We wanted to evaluate the
effects of hbs-LAB supplements relative to no treatment (negative control), placebo
supplements, or antibiotic (tylosin) treatment on four key parameters: (i) colony-level P.
larvae spore prevalence/amounts, (ii) colony-level AFB symptoms, (iii) colony size, and
(iv) amount of brood. These objectives were tested at the most realistic organizational
scale of the superorganism, namely, at the colony level, and changes in spore levels,
clinical symptoms, and colony health were monitored over an entire season. Lastly, the
application scheme for the hbs-LAB followed the recommendation of the producer of
this commercial product, and the tylosin application followed the current practice in
beekeeping. The objectives were tested in both the short term, for the weeks imme-
diately following treatment application, and the long term, covering the entire bee
season. For the analysis we chose a Bayesian analytical framework in order to evaluate
both the probability and the magnitude of any effect detected and because this
approach is ideally suited to analyzing trends in complex study systems, such as
honeybee colonies.
RESULTS
The development of the diseases and the colony health are shown in Fig. 1 and
reﬂect possible effect of the treatments as well as natural dynamics of the colony, such
as the increasing amounts of brood in the spring and smaller amounts of brood in the
autumn. As expected for this complex system, there is great variability among colonies.
This is most obvious for the P. larvae spore levels, which differ by several orders of
magnitude between different samples.
The output of the Bayesian analyses is shown in Tables 1 and 2 (all pairwise
comparisons; see also Fig. S2 in the supplemental material for difference calculation)
and Fig. 2 (model estimates and most important pairwise comparison) and consists of
a series of predictions (probabilities) of whether a particular parameter would increase
or decrease, and by how much, across an entire season (Table 1) or directly after
treatment (Table 2).
The probability of spore levels going up or down after treatment was about 50% for
tylosin, irrespective of whether we looked at the long-term effect over the whole
season (Table 1) (47% chance of an increase) or the short-term effect directly after
treatment (Table 2) (46% chance of an increase). In contrast, there was a very high (89%)
probability of a large (48%) reduction in visible symptoms after tylosin treatment, and
this was even higher (97% probability of a 67% reduction) directly after treatment.
However, tylosin may come with a moderate long-term cost to colony size (11%) and
brood size (21%), with 79% and 72% probability, respectively. This detrimental effect
was also indicated in the short term for the colony size (68% chance of a decrease),
while brood size was not affected immediately (46% chance of an increase).
The trends for the hbs-LAB treatment are slightly different and in many ways more
interesting. Like tylosin, the hbs-LAB had no effect on either short- or long-term spore
levels. However, hbs-LAB treatment did result in a 27% chance of a 61% short-term
increase (meaning a 73% chance of a 61% decrease) in visible clinical symptoms,
although this effect dissipated over the long term (41% chance of a 9.5% increase). This
(desired) reduction, however, should not be overestimated and cannot be entirely
attributed to the hbs-LAB, as the placebo had a similar chance of decreasing the
symptoms compared to the control (72% chance of decrease of 19% in the long term
and 83% chance of 38% decrease in the short term), and clinical symptoms were similar
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in hbs-LAB and control colonies (64% chance in the long term and 56% chance in the
short term of a difference larger than zero). Only small (4.2%) and not very likely (41%
chance) increases in colony size were predicted with hbs-LAB treatment over the short
term. However, we detected a tendency of a small decrease in the long term (28%
chance of an 8.2% increase, meaning a 72% chance of an 8.2% decrease). The hbs-LAB
treatment was also very likely (13% chance of increase, meaning 87% chance of
decrease) to decrease the amount of brood by 75% in the short term, but this effect
also dissipated over time (48% chance of an increase). In summary, it seemed that the
placebo also tended to decrease the clinical symptoms and decreased the colony size
and the brood size, but by performing all comparisons, we could show that hbs-LAB is
unlikely to have any desired effect but, in contrast, may negatively affect colony health.
DISCUSSION
Microbial gut symbionts isolated from the honeybee crop are highly specialized in
performing metabolic activities necessary to honeybees and could be useful to sustain
honeybee health (21, 24, 37). Although several studies have shown favorable effects
from hbs-LAB on bee health and their activity against pathogens in individual bees in
particular, this does not necessarily correspond to similar effectiveness in the honeybee
colony. There are currently very few data available on the effect of supplemental LAB
administration on colony-level bee health and performance. The main objective of this
study was therefore to test whether the inhibitory effects from hbs-LAB on P. larvae
observed in individual bees in laboratory experiments would transfer to honeybee
FIG 1 Original data on the effect of tylosin and hbs-LAB on American foulbrood (AFB) and colony strength. Shown
are AFB spore counts, clinical symptoms, and colony strength represented by colony size (number of frame sides
with bees) and brood size (number of brood) with respect to treatment (control, American foulbrood infection;
tylosin, American foulbrood infection and tylosin treatment; placebo, American foulbrood infection and placebo of
hbs-LAB; hbs-LAB, American foulbrood infection and hbs-LAB). All six sampling occasions are shown for all 40
colonies, with the lines showing the trends between the mean values for the respective treatment and its control.
At the bottom the time course of the treatment application is indicated. Red, tylosin; blue,  placebo/hbs-LAB;
black, boost of infection by inoculating all colonies with AFB spores.
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colonies, leading to lower bacterial spore counts and mitigated symptoms of AFB.
Additionally, we investigated the effect of hbs-LAB supplements on overall colony
strength, i.e., the amount of adult bees and brood. Since AFB is a brood disease, the
amount of brood is a particularly relevant colony-level parameter to investigate.
We detected no effect of tylosin or hbs-LAB on the spore levels of P. larvae in the
colonies in this study. The results are in line with results from an earlier study by Maggi
and coworkers (23), who showed that supplying colonies with organic acids produced
by the bacterium Lactobacillus johnsonii CRL1647 did not change the disease dynamics
of Nosema spp. in honeybee hives despite the inhibitory effects observed in laboratory
studies.
It has been demonstrated that antibiotics such as moxiﬂoxacin, ciproﬂoxacin, lin-
ezolid, meropenem, or doxycycline cannot incapacitate Bacillus anthracis (38), which is
also a Gram-positive bacterium. As expected, the application of the antibiotic tylosin in
our study mitigated visual symptoms of AFB disease, with the most dramatic effect
within 2 months of application, but did not decrease P. larvae spore levels either in the
short term or over the entire season. The absence of changes in the P. larvae spore
levels while visible AFB symptoms decreased clearly illustrates how antibiotic treatment
can hide or “mask” the persistent potential for AFB outbreaks. Furthermore, the
absence of symptoms increases the likelihood that, through normal beekeeping prac-
tices, bees and hive material are exchanged between truly uninfected and asymptom-
atic spore-containing colonies, thus promoting the “hidden” spread of the disease
agent. Prophylactic use of antibiotics for AFB symptom management also facilitates the
emergence of antibiotic-resistant strains of P. larvae (9, 13, 39–41). It has been esti-
mated that in areas where antibiotics are used, 10% to 20% of AFB-infected colonies
would succumb to the disease if the antibiotic treatment ceased or became ineffective
due to the development of antibiotic resistance (42). Beekeeping management tech-
TABLE 1 Pairwise comparison among all treatments in the long term over the whole season (all 6 sampling occasions)a
Explanatory variable Combination % Mean Lower CI Upper CI P [effect > 0] Effect direction
Spore count Tylosin–control 18 217 2,181 3,481 47 1
hbs-LAB–placebo 34 260 1,724 1,799 42 1
hbs-LAB–control 13 156 2,184 2,185 53 2
Placebo–control 35 416 2,549 1,729 63 2
hbs-LAB–tylosin 27 373 2,711 1,724 57 2
Tylosin–placebo 84 633 1,370 3,029 35 1
Clinical symptoms Tylosin–control 48 0.24 0.65 0.13 89 2
hbs-LAB–placebo 9.5 0.04 0.47 0.56 41 1
hbs-LAB–control 11 0.06 0.57 0.35 64 2
Placebo–control 19 0.09 0.52 0.4 72 2
hbs-LAB–tylosin 71 0.18 0.18 0.68 23 1
Tylosin–placebo 36 0.14 0.55 0.36 71 2
Colony size Tylosin–control 11 1.75 6.08 1.89 79 2
hbs-LAB–placebo 8.2 1.24 2.83 4.36 28 1
hbs-LAB–control 0.9 0.15 3.7 3.71 53 2
Placebo–control 8.4 1.39 4.62 2.85 73 2
hbs-LAB–tylosin 11 1.6 2.33 4.86 25 1
Tylosin–placebo 2.4 0.36 3.6 3.24 57 2
Brood size Tylosin–control 21 23.51 85.7 44.47 72 2
hbs-LAB–placebo 3.1 2.59 50.02 57.24 48 1
hbs-LAB–control 24 27.08 89.99 37.14 76 2
Placebo–control 26 29.67 94.17 30.81 77 2
hbs-LAB–tylosin 4 3.57 66.46 51.68 54 2
Tylosin–placebo 7.4 6.15 54.97 55.03 44 1
aThe most relevant comparison, the treatment and its respective control, is shown in the ﬁrst two rows for each variable. Each comparison represents the posterior
density of the differences derived by subtracting the posterior of one treatment from the posterior of the other treatment. The posterior density of the difference is
described by the mean and the upper and lower credibility intervals (highest posterior density interval) as well as the difference in percentage and the probability
density above zero (P [effect  0]). In the last column the direction of the effect is speciﬁed. For example, the ﬁrst row speciﬁes that there is a 47% chance that the
treatment tylosin will lead to an 18% increase in spore counts compared to the control, which is close to the 50% that would occur just by chance.
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niques to avoid the spread of the disease to other colonies and areas, supplemented by
the destruction of symptomatic honeybee colonies, as practiced in many countries, is
a more sustainable way to control AFB and to avoid contributing to the development
of antibiotic resistance (17, 43).
Another reason for ﬁnding better ways for disease control is the harmful effect of
the antibiotic on the colony. In our study, we found some indication that tylosin may
negatively affect the long-term honeybee colony development, with both colony size
and brood size more likely to decrease than increase, relative to the untreated control.
These contrasting effects of tylosin (immediate reduction in symptoms versus long-
term reduction in colony strength) are difﬁcult to interpret within the context of AFB
development. AFB is a devastating brood disease that severely limits the ability of the
colony to adequately replace its adult population, leading to dwindling colony size,
diminished brood production, and ultimately colony demise. The colony would natu-
rally use all its available homeostatic mechanisms to compensate for this deﬁcit in order
to survive, especially in the early stages of the disease, which could include extra
emphasis on brood rearing. This may be one indirect explanation for the difference in
brood size between treated and untreated colonies. The counterargument, that tylosin
directly kills brood at a higher rate than uncontrolled AFB, is more difﬁcult to sustain
given the clear observed positive effect on reducing symptoms, which would only
beneﬁt brood development and normal population turnover. Surprisingly, the direct
effects of antibiotics on colony strength parameters in uninfected colonies are not well
documented. One similar study also found that colony size (bee numbers) in AFB-
affected colonies decreased by 50% if the colony was treated with tylosin (12), although
the responses were quite variable and inconsistent. Although not directly comparable,
one study on the application of fumagillin (an antimicrobial agent used to against the
pathogen Nosema ceranae [44]) found no difference in bee numbers and brood size
TABLE 2 Comparison among all treatments in the short term for the sampling immediately after the treatment application (occasions 3
and 4)a
Explanatory variable Combination % Mean Lower CI Upper CI P [effect > 0] Effect direction
Spore count Tylosin–control 2.3 90 8,149 6,554 46 1
hbs-LAB–placebo 49 3,967 8,156 6,866 53 2
hbs-LAB–control 4 156 7,560 7,402 50 1
Placebo–control 110 4,124 7,519 9,533 47 1
hbs-LAB–tylosin 1.7 67 6,386 8,847 56 1
Tylosin–placebo 50 4,033 7,930 7,262 49 2
Clinical symptoms Tylosin–control 67 0.83 1.84 0 97 2
hbs-LAB–placebo 61 0.47 0.72 1.68 27 1
hbs-LAB–control 0.19 0 1.33 1.14 56 2
Placebo–control 38 0.47 1.38 0.53 83 2
hbs-LAB–tylosin 200 0.82 0.27 1.98 7.7 1
Tylosin–placebo 47 0.36 1.02 0.45 83 2
Colony size Tylosin–control 6 0.82 4.95 3.12 68 2
hbs-LAB–placebo 4.2 0.6 3.19 5.69 41 1
hbs-LAB–control 9.4 1.28 2.14 6.23 28 1
Placebo–control 5 0.69 3.47 4.73 38 1
hbs-LAB–tylosin 16 2.1 1.88 7.2 18 1
Tylosin–placebo 11 1.5 6.18 1.61 78 2
Brood size Tylosin–control 5.1 7.86 119.57 96.41 46 1
hbs-LAB–placebo 75 95.91 45.78 219.67 13 1
hbs-LAB–control 45 69.12 79.44 198.46 21 1
Placebo–control 17 26.79 123.35 70.46 63 2
hbs-LAB–tylosin 38 61.25 75.93 191.58 24 1
Tylosin–placebo 27 34.66 66.29 141.04 31 1
aThe most relevant comparison, the treatment and its respective control, is shown in the ﬁrst two rows for each variable. Each comparison represents the posterior
density of the differences derived by subtracting the posterior of one treatment from the posterior of the other treatment. The posterior density of the difference is
described by the mean and the upper and lower credibility intervals (highest posterior density interval) as well as the difference in percentage and the probability
density above zero (P [effect  0]). In the last column the direction of the effect is speciﬁed. For example, in row eight there is a 27% chance that hbs-LAB will
increase the symptoms compared to the placebo, meaning that there is a 73% chance that hbs-LAB will decrease the symptoms.
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between treated and untreated colonies 2 months after application (45). Thus, our
study reports the probability and magnitude of negative effects from antibiotic use on
colony strength.
The application of hbs-LAB as treatment against AFB does not seem to be a viable
option, as neither the spore counts nor the clinical symptoms decreased. Looking only
at data from the two sampling occasions directly posttreatment, the probability of
ﬁnding a decrease in symptoms was higher (a 73% chance) than that of ﬁnding an
increase (a 27% chance), compared to the placebo treatment. Nevertheless, the hbs-
LAB effect did not differ from that of the control, and we interpret this result as being
unlikely to change the disease status of a colony. The contrasting results between
individual and colony-level applications of beneﬁcial microbes therefore highlight the
strength of the honeybee homeostatic mechanisms in neutralizing the effects of any
attempt to manipulate the natural conditions of the colony (46, 47). Due to the
complexity of a honeybee colony, results obtained in laboratory experiments do not
necessarily translate into an effective treatment for honeybee colonies (30).
A recent ﬁeld study by De Piano et al. (66) showed that honeybee colony perfor-
mance did not change after administration of Lactobacillus johnsonii AJ5 metabolites.
On the other hand, in another ﬁeld study, administration of a monoculture of Bacillus
subtilis subsp. subtilis Mori2 to honeybee colonies was shown to stimulate the queen’s
egg laying and consequently lead to an increased number of individuals in treated
colonies (19). Those data are supported by our study with signs that hbs-LAB applica-
tion does increase colony strength, since an increase in brood size right after the
FIG 2 Model predictions of the effect of tylosin and hbs-LAB on American foulbrood and colony strength. Shown
are predictions for a whole season (all six sampling occasions) (left side) and predictions for sampling right after
the application of the hbs-LAB treatment (right side). The estimates and the difference show the mean value from
1,000 samples of the respective posterior with 89% credibility intervals (highest posterior density intervals). Each
difference represents the posterior obtained by subtracting the posterior of one treatment by the posterior of the
other treatment.
Effect of Lactic Acid Bacteria and Tylosin on AFB Applied and Environmental Microbiology
July 2019 Volume 85 Issue 13 e00606-19 aem.asm.org 7
 o
n
 O
ctober 30, 2019 at SVERIG
ES LANTBRUKSUNIVERSITET
http://aem
.asm
.org/
D
ow
nloaded from
 
application was likely (87%) and potentially strong (95.9% [89% credibility interval {CI},
45.8 to 219.7%] occupied grids with brood, around 75% more than that with the
placebo treatment). However, this beneﬁt was short-lived, as over the season it could
no longer be detected.
Regarding the effect of the treatments on colony strength, we could show that there
is little beneﬁt from applying hbs-LAB, but it is certainly disadvantageous for colony
development to apply tylosin. The gut microbiome plays a key role in animal health,
including that of honeybees, and the exposure to antibiotics has detrimental effects
perturbing the native honeybee gut community (48, 49). The use of the antibiotic
tetracycline in honeybee colonies led to elevated mortality of individual adult bees and
an increased susceptibility to experimental infection with the opportunistic bacterial
pathogen Serratia (49). Furthermore, Li and coworkers noticed that perturbation of the
gut microbiome by antibiotics weakened the immune function and made honeybees
more susceptible to experimental Nosema infection (41). Many other studies (3, 23, 50,
51) highlight that the gut microbiome is of great importance for the health of
honeybees. This is yet another reason for exploring alternatives to antibiotics for
combatting diseases in beekeeping. Most hbs-LAB are highly sensitive to antibiotics
such as tylosin and oxytetracycline (52). The long-term use of antibiotics for treatment
and control of bacterial diseases in beekeeping perturbs the balance of the honeybee
gut microbiome, including hbs-LAB, and affect honeybee health.
The aim of the study was to test hbs-LAB application at the most relevant spatial and
temporal scales. However, to gain a mechanistic understanding of the relationship
between microbiota and pathogen prevalence in honeybees, future studies will need to
better understand the dynamics within a colony. For example recent results indicate
that hbs-LAB diversity is very variable over a season, that there is greater diversity in
colonies with an AFB history, but that AFB spore levels are unrelated to hbs-LAB levels
(S. Lamei et al., unpublished data).
In conclusion, this work does not refute the beneﬁcial nature of honey crop bacteria
as has been abundantly shown previously (24, 27, 36, 52), but it does show that
translating this knowledge into a useful application is not straightforward and requires
careful consideration of the social character and the natural homeostatic mechanisms
governing health, microbiome diversity, and function in honeybee colonies (3, 34).
Moreover, it conﬁrms that neither supplemental hbs-LAB nor the antibiotic tylosin has
short- or long-term effects on the spore levels of P. larvae, the causative agent of AFB,
thus maintaining the infection pressure and the risk of disease outbreaks.
MATERIALS AND METHODS
Experimental design. Forty honeybee colonies headed by queens of the same age from a single
queen breeder were established on 24 March 2014 using 1.2-kg packages of honeybees in an isolated
apiary in Beltsville, MD, USA. The colonies were placed in an apiary with a history of AFB, and the frames
and boxes used came from colonies that were managed with AFB in previous studies. All colonies in this
apiary would have had some exposure to AFB, but to ensure exposure, all colonies were given a standard
spore suspension as described below. The colonies were fed three times with a 1:1 sucrose-water
solution to help establish the colonies and promote growth of adult bee populations. The colonies were
assessed and inspected on 23 April for the presence of AFB, and AFB severity was rated as noted below.
The colonies were assigned to the treatment groups using a stratiﬁed random design; i.e., colonies were
ranked according to AFB severity and divided into groups of four down the ranking, with subsequent
random treatment assignment within each ranking group; each colony in each ranking group received
one of the following treatments in a double-blinded fashion: (i) antibiotic (tylosin), (ii) hbs-LAB placebo,
(iii) hbs-LAB supplement, and (iv) no treatment (control). All 40 colonies in the AFB apiary were
inoculated on 1 May 2014 with P. larvae to boost the onset of AFB, by spraying 2 combs of unsealed
brood in each colony with 5 ml of a sucrose solution containing approximately 0.2 109 P. larvae spores.
The hbs-LAB supplement and the placebo supplement were, as recommended by the producer,
administered on two occasions, 23 to 25 April and 7 to 9 May 2014, 1 week before and 1 week after AFB
inoculation. The tylosin treatment was administered on 13 May, 12 days after AFB inoculation, as we
expected the infection to establish then. The colonies were sampled, assessed, and inspected for AFB
symptoms on 6 occasions between April and August 2014: on 23 April (day 1), 13 May (day 21), 29 May
(day 37), 12 June (day 51), 10 July (day 79), and 5 August (day 105) (Fig. 1).
Preparation of the tylosin and hbs-LAB treatments. SymBeeotic, a proprietary mixture of hbs-LAB
species, was used as a supplement in honeybee colonies. This hbs-LAB mixture consisted of 13 viable
species of hbs-LAB (Lactobacillus kunkeei Fhon2N, Lactobacillus apinorum Fhon13N, Lactobacillus mellis
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Hon2N, Lactobacillus mellifer Bin4N, Lactobacillus apis Hma11N, Lactobacillus helsingborgensis Bma5N,
Lactobacillus melliventris Hma8N, Lactobacillus kimbladii Hma2N, Lactobacillus kullabergensis Biut2N,
Biﬁdobacterium asteroides Bin2N, Biﬁdobacterium asteroides Bin7N, Biﬁdobacterium asteroides Hma3N, and
Biﬁdobacterium coryneforme Bma6N), with a total cell count of 109 CFU/g honey (26, 27, 53), mixed with
sterilized (102°C for 30 min) Swedish heather honey. SymBeeotic was prepared and given to the colonies
according to the manufacturer’s instructions, as follows. Each SymBeeotic bag was added to 1.5 kg
inverted sugar solution diluted with 1 liter of warm water (45°C). This mixture was kept between 30 and
40°C overnight, and around 73 ml of this mixture per colony was used for feeding honeybees. The same
preparation and administration procedure was followed for the placebo treatment, which consisted of
just sterilized Swedish heather honey, without hbs-LAB. For the antibiotic treatment, 200 mg tylosin
tartrate was applied per colony in 20 g of ﬁnely powered confectioners’ sugar (Domino sugar 10X).
Sample collection. Approximately 200 adult honeybees per sample were collected from the brood
chamber in a small cardboard box and stored at 20°C until further analysis.
Colony assessments. Colony strength and development were assessed on each of the 6 sampling
occasions of the experiment. The amount of brood was assessed by counting the number of 5- by 5-cm
sections on both sides of each frame occupied with sealed brood. A single side of one Langstroth frame
is equal to 32 such 5- by 5-cm sections (54). The number of adult bees was assessed by counting the
number of frame sides covered with adult bees (55). For brood and adults separately, the estimates for
each side of all frames were summed to produce composite brood and adult bee scores for the entire
colony.
AFB severity assessment. The severity of AFB disease was determined by removing each frame and
making a visual inspection of the brood (immature larval and pupal honeybees) for evidence of infection.
AFB is easy to identify in the ﬁeld, since the disease symptoms are highly diagnostic. These include
partially uncapped cells, a foul odor, and the presence of dead and decaying (pre)pupae within cells.
Samples of diseased brood were taken for positive laboratory identiﬁcation to conﬁrm the ﬁeld
diagnoses. Colonies were rated according to the severity of AFB infection as described by Pettis and
Feldlaufer (16); this is the recommended grading system for AFB (56). Each frame side with brood was
rated for AFB infection on a scale of 0 to 3: 0, no visible signs of disease; 1, fewer than 10 diseased brood
cells; 2, 11 to 100 diseased cells; and 3, more than 100 diseased cells. The scores for each side of all frames
were summed to produce a composite AFB score for the entire colony.
Cultivation of P. larvae from honeybee samples. Worker honeybee samples were crushed and
cultivated on Mueller-Hinton broth–yeast extract–potassium phosphate–glucose–pyruvate (MYPGP)
agar plates as described previously (57). The numbers of P. larvae colonies were counted, and the data
were presented as CFU per honeybee.
Data analysis. The data consisted of 6 sets of measurements with 10 replications (honeybee
colonies) for each treatment group, except for 2 colonies that died during the experiment (day 79,
placebo; day 105, tylosin). The data were analyzed using multilevel Bayesian linear models, since these
models can account for all uncertainty in the data (58, 59). Contrary to the frequentist approach, which
calculates the probability of obtaining the observed data given a particular hypothesis (tested with P
values), the Bayesian approach calculates the probability of the hypothesis given the observed data. The
results of the Bayesian models are posterior probability distributions for each of the parameters modeled,
from which probabilistic statements about the size and direction of possible effects can be made.
Differences between treatments can be calculated by subtracting one posterior distribution from the
other (see Fig. S2 in the supplemental material).
All models included the treatment as the main factor to be analyzed. Since in these analyses we were
interested primarily in the effect of treatment over the entire season, we included sampling date as a
random effect, thereby accounting for the repeated-measure structure of the sampling. We furthermore
included colony ID and each observation as random effects (see Appendix for model structures).
Differences among the colonies were therefore accounted for and each observation received its own
likelihood, meaning model overdispersion was not possible (60). Although the ﬁrst sampling occasion
was prior to both treatment and AFB booster inoculation, we decided to include all 6 sampling occasions
in the analyses, since we were interested primarily in the overall effect across the entire season and AFB
spores and symptoms were also present on sampling occasion 1, before the AFB booster inoculation, as
part of the natural conditions of the AFB apiary (see “Experimental design” above). In order to separate
the more immediate and the whole-season effects of the tylosin or hbs-LAB treatments, we build models
with different subsets of the data. For these short-term models we included sampling occasions 3 and
4 (days 37 and 51), since these were within 1 month after application of the treatments and effects on
the colony are likely to be delayed (49).
In total we built 8 models: 4 with all data from all sampling occasions and 4 with the data from
sampling occasions 3 and 4. From the posteriors we calculated the mean value and the 89% credible
intervals (highest posterior density intervals; see Fig. S2 for an explanation). We then calculated the
differences between the treatments and the control by subtracting the posterior of the control from
the posterior of the treatment. In addition, the remaining 4 combinations were also calculated. For each
we calculated the absolute difference (mean  credibility intervals compared to the control values), the
relative difference in percentage (with control values as a reference), and the probability that the
differences are larger than zero (P [effect  0]; in case of the treatment being smaller than the control,
e.g., P [effect  0]  90% would indicate a 9 in 10 chance of a decrease due to the treatment).
All response variables are counts and therefore received a Poisson likelihood (log link function).
Although the AFB score actually represents a mixture of ordinal (0 to 3) and continuous (sum of 0 to 3
per frame side for each colony) scales, here we used the ﬁnal scores as counts. In all models, we used
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minimal informative priors (see Appendix) that were updated with the data to arrive at the posterior
distributions for each parameter. The Bayesian Markov chain Monte Carlo (MCMC) methodology was
performed with 2,000 iterations (Hamilton Monte Carlo; 1,000 warm up, 1,000 sampling the chains). The
models were validated running 3 chains (no major differences were found between these), using the
Gelman and Rubin diagnostic (Rˆ between 1 and 1.02), inspecting the effective number of independent
samples form the posterior (worst cases, 100 samples), and comparing the predictions with the original
data (see an example in Fig. S1 in the supplemental material). The analysis was performed using R (61)
and Stan (62) by using functions provided in reference 63. The data were well described in all models
(Fig. S1), and we could determine posterior probability distributions for all four response variables (P.
larvae spore levels, AFB symptoms, colony size and brood size [Fig. 1]) and for all calculated differences.
APPENDIX
MODEL STRUCTURE OF ALL EIGHT MODELS
Response variablei  Poisson(i)
Log(i)  Control  Antibiotic Antibiotici  Placebo Placeboi  hbs-LAB hbs-LABi 
Colony[i]  Day[i]  Observation[i]
Control  Normal(0, XX)
Antibiotic  Normal(0, XX)
Placebo  Normal(0, XX)
hbs-LAB  Normal(0, XX)
Colony  Normal(0, Colony)
Colony  Exp(1)
Day  Normal(0, Day)
Day  Exp(1)
Observation  Normal(0, Observation)
ObservationID  Exp(1)
For the models with all six or with only occasions 3 and 4, the XX sigma was
as follows: spore count  10, clinical symptoms  1, colony size  1, and brood
size  10.
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Page 4: Figure 1 should appear as shown below.
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Page 7: Figure 2 should appear as shown below.
Page 7, paragraph 3, lines 6 and 7: “Those data are supported by our study with
signs that hbs-LAB application does increase colony strength, since an increase in
brood size. . .” should read “Those data are not supported by our study with signs that
hbs-LAB application does decrease colony strength, since a decrease in brood size. . . .”
Page 8, paragraph 1, line 2: “around 75% more” should read “around 75% less.”
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